Disease-modifying effects of orally bioavailable NF-κB inhibitors in dystrophin-deficient muscle

David W. Hammers(University of Florida), H. Lee Sweeney(University of Pennsylvania)
JCI Insight
December 21, 2016
Cited by 50


Related Papers